Thorbald van Hall

List of Publications by Year
in descending order

109 papers	8,034 citations	61984 43 h-index	54911 84 g-index
115 all docs	115 docs citations	115 times ranked	11690 citing authors

#	Article	IF	Citations
1	Therapeutic cancer vaccines. Journal of Clinical Investigation, 2015, 125, 3401-3412.	8.2	640
2	Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature Reviews Cancer, 2016, 16, 219-233.	28.4	580
3	The urgent need to recover MHC class I in cancers for effective immunotherapy. Current Opinion in Immunology, 2016, 39, 44-51.	5.5	464
4	M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells. Journal of Immunology, 2011, 187, 1157-1165.	0.8	334
5	Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein. Journal of Experimental Medicine, 1999, 190, 1033-1038.	8.5	305
6	The PD-1/PD-L1-Checkpoint Restrains TÂcell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell, 2020, 38, 685-700.e8.	16.8	299
7	NKG2A Blockade Potentiates CD8ÂT Cell Immunity Induced by Cancer Vaccines. Cell, 2018, 175, 1744-1755.e15.	28.9	241
8	Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight, 2018, 3, .	5.0	216
9	DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells. Cancer Research, 2007, 67, 1317-1325.	0.9	198
10	Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 1997, 186, 695-704.	8.5	196
11	Monalizumab: inhibiting the novel immune checkpoint NKG2A. , 2019, 7, 263.		182
12	HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10656-10661.	7.1	175
13	Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells. Journal of Biological Chemistry, 2007, 282, 21145-21159.	3.4	157
14	Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and Tâ€cell activation. European Journal of Immunology, 2013, 43, 2554-2565.	2.9	157
15	Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nature Medicine, 2006, 12, 417-424.	30.7	142
16	Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6730-6735.	7.1	132
17	PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. OncoImmunology, 2017, 6, e1294299.	4.6	114
18	Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. Cancer Immunology Research, 2017, 5, 535-546.	3.4	108

#	Article	IF	Citations
19	Tumorâ€infiltrating CD14â€positive myeloid cells and CD8â€positive Tâ€cells prolong survival in patients with cervical carcinoma. International Journal of Cancer, 2013, 133, 2884-2894.	5.1	106
20	The NKG2Aâ€“HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. Clinical Cancer Research, 2020, 26, 5549-5556.	7.0	101
21	Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28. Journal of Experimental Medicine, 2000, 192, 483-494.	8.5	100
22	Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nature Immunology, 2011, 12, 45-53.	14.5	94
23	Antiâ€inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitorâ€treated gastrointestinal stromal tumors. International Journal of Cancer, 2010, 127, 899-909.	5.1	92
24	Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment. Cancer Immunology, Immunotherapy, 2017, 66, 903-912.	4.2	92
25	Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. Clinical Cancer Research, 2011, 17, 5668-5673.	7.0	91
26	The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. Journal of Experimental Medicine, 2010, 207, 207-221.	8.5	89
27	Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site. Journal of Immunology, 2000, 164, 1898-1905.	0.8	88
28	Strategies to counteract MHC-I defects in tumors. Current Opinion in Immunology, 2011, 23, 293-298.	5.5	87
29	Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Molecular Immunology, 2013, 53, 126-131.	2.2	85
30	In Aged Mice, Outgrowth of Intraocular Melanoma Depends on Proangiogenic M2-Type Macrophages. Journal of Immunology, 2010, 185, 3481-3488.	0.8	82
31	Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100. Cancer Research, 2009, 69, 7784-7792.	0.9	81
32	Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome. Frontiers in Immunology, 2015, 6, 298.	4.8	73
33	The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget, 2016, 7, 3477-3488.	1.8	73
34	Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes. PLoS ONE, 2016, 11, e0164292.	2.5	72
35	Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. Cancer Immunology Research, 2015, 3, 1042-1051.	3.4	68
36	Identification of non-mutated neoantigens presented by TAP-deficient tumors. Journal of Experimental Medicine, 2018, 215, 2325-2337.	8.5	64

#	Article	IF	Citations
37	Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers, 2021, 13, 287.	3.7	61
38	TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. Journal of Clinical Investigation, 2016, 126, 784-794.	8.2	60
39	The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes and Infection, 2010, 12, 910-918.	1.9	59
40	Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNÎ³ receptor signaling. , 2019, 7, 152.		57
41	CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory. Molecular Cancer Therapeutics, 2019, 18, 312-322.	4.1	57
42	Expression of a Natural Tumor Antigen by Thymic Epithelial Cells Impairs the Tumor-Protective CD4+ T-Cell Repertoire. Cancer Research, 2005, 65, 6443-6449.	0.9	55
43	Immunotherapeutic Potential of TGF-Î² Inhibition and Oncolytic Viruses. Trends in Immunology, 2020, 41, 406-420.	6.8	55
44	Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy. PLoS ONE, 2014, 9, e104230.	2.5	52
45	Peptide Vaccination after T-Cell Transfer Causes Massive Clonal Expansion, Tumor Eradication, and Manageable Cytokine Storm. Cancer Research, 2010, 70, 8339-8346.	0.9	47
46	Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nature Communications, 2019, 10, 3773.	12.8	47
47	Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma. Oncotarget, 2015, 6, 37824-37835.	1.8	46
48	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Seminars in Immunology, 2013, 25, 182-190.	5.6	44
49	Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin. Journal of Immunology, 2000, 165, 869-877.	0.8	43
50	Future Challenges in Cancer Resistance to Immunotherapy. Cancers, 2020, 12, 935.	3.7	41
51	The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment. European Journal of Cancer, 2017, 86, 285-295.	2.8	40
52	Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy. , 2020, 8, e001191.		40
53	Digital PCR-Based T-cell Quantificationâ€“Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma. Molecular Cancer Research, 2018, 16, 1902-1911.	3.4	39
54	Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL. Journal of Immunology, 2011, 187, 5532-5539.	0.8	37

#	Article	IF	Citations
55	CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy. Cancer Immunology Research, 2017, 5, 642-653.	3.4	37
56	The Varicellovirus-Encoded TAP Inhibitor UL49.5 Regulates the Presentation of CTL Epitopes by Qa-1b1. Journal of Immunology, 2007, 178, 657-662.	0.8	36
57	TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers. Molecular Immunology, 2019, 113, 43-49.	2.2	36
58	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
59	New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation. Journal of Immunology, 2013, 191, 4020-4028.	0.8	35
60	Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut, 2022, 71, 2266-2283.	12.1	35
61	CD8+ T Cell Responses against TAP-Inhibited Cells Are Readily Detected in the Human Population. Journal of Immunology, 2010, 185, 6508-6517.	0.8	34
62	Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires. European Journal of Immunology, 2011, 41, 3114-3124.	2.9	33
63	Arming oncolytic reovirus with GM-CSF gene to enhance immunity. Cancer Gene Therapy, 2019, 26, 268-281.	4.6	33
64	Induction of Protective CTL Immunity against Peptide Transporter TAP-Deficient Tumors through Dendritic Cell Vaccination. Cancer Research, 2007, 67, 8450-8455.	0.9	31
65	A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens. Cancer Immunology, Immunotherapy, 2012, 61, 119-125.	4.2	31
66	Importance of TAP-independent processing pathways. Molecular Immunology, 2013, 55, 113-116.	2.2	29
67	Improved SÃ©zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in SÃ©zary syndrome. Blood, 2021, 138, 2539-2554.	1.4	28
68	Characterization of Antigen-Specific Immune Responses Induced by Canarypox Virus Vaccines. Journal of Immunology, 2007, 179, 6115-6122.	0.8	26
69	Evidence for Natural Killer Cellâ€“Mediated Protection from Metastasis Formation in Uveal Melanoma Patients. , 2009, 50, 2888.		26
70	The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. Journal of Experimental Medicine, 2010, 207, 671-671.	8.5	25
71	Mechanisms of Peptide Vaccination in Mouse Models. Advances in Immunology, 2012, 114, 51-76.	2.2	25
72	T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant Lymphocytes. Frontiers in Immunology, 2018, 9, 60.	4.8	25

#	Article	IF	Citations
73	Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse Melanoma. Journal of Immunology, 2013, 190, 489-496.	0.8	24
74	Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Molecular Immunology, 2011, 48, 835-845.	2.2	22
75	Proline substitution independently enhances <scp>H</scp>â€2<scp>D</scp>^b complex stabilization and <scp>TCR</scp> recognition of melanomaâ€associated peptides. European Journal of Immunology, 2013, 43, 3051-3060.	2.9	22
76	<scp>NKG2A</scp> is a late immune checkpoint on <scp>CD8</scp> T cells and marks repeated stimulation and cell division. International Journal of Cancer, 2022, 150, 688-704.	5.1	22
77	Joint-Derived T Cells in Rheumatoid Arthritis Proliferate to Antigens Present in Autologous Synovial Fluid. Scandinavian Journal of Rheumatology, 1995, 24, 169-177.	1.1	19
78	T cells specific for a TAP-independent self-peptide remain naÃ¯ve in tumor-bearing mice and are fully exploitable for therapy. OncoImmunology, 2018, 7, e1382793.	4.6	18
79	Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. , 2020, 8, e001326.		16
80	To TAP or not to TAP: alternative peptides for immunotherapy of cancer. Current Opinion in Immunology, 2020, 64, 15-19.	5.5	16
81	Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights. International Journal of Molecular Sciences, 2021, 22, 9401.	4.1	16
82	Effective Immunotherapy of Cancer in MUC1-Transgenic Mice Using Clonal Cytotoxic T Lymphocytes Directed Against an Immunodominant MUC1 Epitope. Journal of Immunotherapy, 2002, 25, 46-56.	2.4	14
83	Infiltrating CTLs are bothered by HLA-E on tumors. OncoImmunology, 2012, 1, 92-93.	4.6	14
84	A Restricted Role for FcÎ³R in the Regulation of Adaptive Immunity. Journal of Immunology, 2018, 200, 2615-2626.	0.8	14
85	Interleukinâ€6â€mediated resistance to immunotherapy is linked to impaired myeloid cell function. International Journal of Cancer, 2021, 148, 211-225.	5.1	13
86	Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S. , 2022, 10, e003591.		13
87	Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire. Molecular Immunology, 2014, 62, 129-136.	2.2	12
88	The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer. Journal of Immunology, 2016, 196, 2327-2334.	0.8	12
89	Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?. Cancers, 2019, 11, 1127.	3.7	12
90	FcÎ³R interaction is not required for effective antiâ€PDâ€L1 immunotherapy but can add additional benefit depending on the tumor model. International Journal of Cancer, 2019, 144, 345-354.	5.1	12

#	Article	IF	Citations
91	Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors. Cancer Immunology Research, 2020, 8, 856-868.	3.4	12
92	PD-L1 immune suppression in cancer: Tumor cells or host cells?. OncoImmunology, 2017, 6, e1325982.	4.6	11
93	High FcÎ³R Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy. Journal of Immunology, 2018, 201, 3741-3749.	0.8	11
94	Promiscuous Binding of Invariant Chain-Derived CLIP Peptide to Distinct HLA-I Molecules Revealed in Leukemic Cells. PLoS ONE, 2012, 7, e34649.	2.5	10
95	IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. , 2021, 9, e002460.		10
96	FcÎ³RI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines. Oncotarget, 2018, 9, 29392-29402.	1.8	10
97	The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability. Journal of Immunology, 2018, 200, 2860-2868.	0.8	8
98	TEIPP peptides: exploration of unTAPped cancer antigens. OncoImmunology, 2019, 8, 1599639.	4.6	8
99	Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. Cancer Genetics and Cytogenetics, 2002, 139, 126-132.	1.0	7
100	Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models. , 2020, 8, e000877.		7
101	A herpesvirus encoded Qa-1 mimic inhibits natural killer cell cytotoxicity through CD94/NKG2A receptor engagement. ELife, 2018, 7, .	6.0	7
102	Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment. Scientific Reports, 2020, 10, 3933.	3.3	6
103	Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	5
104	Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective observational studies. PLoS ONE, 2022, 17, e0261826.	2.5	5
105	Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy. Molecular Cancer Therapeutics, 2022, 21, 1393-1405.	4.1	3
106	Targeting host B-cell immune responses by persistent donor NK-cell alloreactivity following nonmyeloablative allogeneic stem cell transplantation. Blood, 2007, 109, 5524-5525.	1.4	2
107	Limited Density of an Antigen Presented by RMA-S Cells Requires B7-1/CD28 Signaling to Enhance T-Cell Immunity at the Effector Phase. PLoS ONE, 2014, 9, e108192.	2.5	1
108	A Single-Domain TCR-like Antibody Selective for the Qa-1b/Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint. Journal of Immunology, 2022, 208, 2246-2255.	0.8	1

#	Article	IF	Citations
109	Enhanced immunogenicity of MHC class I-restricted tumor-associated altered peptide ligands. Molecular Immunology, 2012, 51, 33-34.	2.2	0